Poster Hall | RheumNow

Poster Hall

AbbVie July 2025

Real-world switching patterns among patients with PsA receiving first-line advanced therapy

Save

Sponsored by AbbVie Medical Affairs + Health Impact

Jul 25, 2025

AbbVie July 2025

Real-world effectiveness in PsA after first-line TNFi: JAKi, IL-17i, or another TNFi

Save

Sponsored by AbbVie Medical Affairs + Health Impact

Jul 25, 2025

AbbVie July 2025

Long-term safety of a JAKi across ~17,000 patient-years

Save

Sponsored by AbbVie Medical Affairs + Health Impact

Jul 25, 2025

More Virtual Posters

AbbVie March 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Real-world outcomes in patients with RA remaining on first-line TNFi

AbbVie March 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Time to first musculoskeletal response of an IL-23i in PsA

AbbVie March 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Long-term maintenance of response of an IL-23i in PsA

Sponsored by UCB

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies

Sponsored by Sanofi

Effectiveness of IL-6 Receptor Inhibitors versus Methotrexate or any Conventional Immunomodulators in Patients with Steroid Refractory Polymyalgia Rheumatica

Sponsored by UCB

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies

Sponsored By Amgen

Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

Sanofi RNL Poster

Sponsored By Sanofi

Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

Abbvie Zoster Virtual Poster

Sponsored by AbbVie Medical Affairs

Zoster vaccine immunogenicity with JAKi treatment

Novartis November Poster

Sponsored by Novartis Medical Affairs

A US Patient Perspective on the Diagnosis and Burden of AxSpA

AbbVie Poster (Sept 2024)

Sponsored by AbbVie Medical Affairs

Safety of a JAKi Across 15,000 Patient-Years of Data

Sponsored by UCB Pharma Medical Affairs

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

UCB Eular Poster

Sponsored by UCB Pharma Medical Affairs

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

AbbVie Poster 2024

Sponsored by AbbVie Medical Affairs

Safety and Efficacy of a JAKi in Patients With Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 From the SELECT-CHOICE Study

Sponsored by UCB Pharma

Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

RNL2024 Poster Submission - Pfizer

Sponsored by Pfizer

Non-Pharmacologic Interventions for Rheumatoid Arthritis

Sponsored by CorEvitas, LLC. And UCB Pharma

Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry

Remission Poster RNL2024

Sponsored By Amgen

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients With Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

Sponsored by AbbVie Medical Affairs

Safety and Efficacy of a JAKi in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years From the SELECT-BEYOND Study

Sponsored by Bristol Myers Squibb

Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

Bimekizumab Poster

Sponsored by UCB

Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

×